KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Inovio Pharmaceuticals (INO) over the last 16 years, with Q3 2025 value amounting to -$350130.0.

  • Inovio Pharmaceuticals' Change in Accured Expenses rose 8230.56% to -$350130.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$874216.0, marking a year-over-year decrease of 38020.19%. This contributed to the annual value of -$3.4 million for FY2024, which is 9267.85% up from last year.
  • As of Q3 2025, Inovio Pharmaceuticals' Change in Accured Expenses stood at -$350130.0, which was up 8230.56% from $2.7 million recorded in Q2 2025.
  • Inovio Pharmaceuticals' Change in Accured Expenses' 5-year high stood at $67.1 million during Q2 2022, with a 5-year trough of -$40.7 million in Q1 2023.
  • In the last 5 years, Inovio Pharmaceuticals' Change in Accured Expenses had a median value of -$350130.0 in 2025 and averaged $397024.6.
  • Over the last 5 years, Inovio Pharmaceuticals' Change in Accured Expenses had its largest YoY gain of 116891.69% in 2022, and its largest YoY loss of 101798.88% in 2022.
  • Over the past 5 years, Inovio Pharmaceuticals' Change in Accured Expenses (Quarter) stood at $18.9 million in 2021, then tumbled by 72.0% to $5.3 million in 2022, then decreased by 11.92% to $4.7 million in 2023, then plummeted by 79.07% to $973719.0 in 2024, then plummeted by 135.96% to -$350130.0 in 2025.
  • Its last three reported values are -$350130.0 in Q3 2025, $2.7 million for Q2 2025, and -$4.2 million during Q1 2025.